Serine protease thrombin is a strong neurotoxin produced by the injured brain and an Alzheimer's disease biomarker. To address its point-of-care testing (POCT), we adapted the O₂-dependent aptamer assay for thrombin to gold screen-printed electrodes (Au SPE). The assay exploits reagentless (with no mediators) electrocatalytic activity of hemin-G4 DNAzyme in O₂ reduction. Au SPEs modified with thiolated hemin-conjugated aptamer and PEG showed enhanced electrocatalytic activity in O₂ reduction upon thrombin binding to the aptamer, then folding into the electroactive hemin-G4 DNAzyme structure. 0.5 fM thrombin were detected in aerated PBS and artificial cerebrospinal fluid, correspondingly, with the logarithmic linear range extending to 100 fM; dopamine, and uric and ascorbic acids did not interfere with electroanalysis. The disposable aptasensor met basic POCT requirements, with a minimal shelf life of 3 days. However, the reactivity and suitability of the Au SPE surface for thiol binding and electrocatalysis required special surface pre-treatment and modification protocols, and the fundamental problem of a long-term stability of thiol modification on gold should be addressed for practical applications of Au SPE-based apatasensors in POCT.